Recombinant activated factor VII in cardiac surgery: Single-center experience

Asian Cardiovascular and Thoracic Annals

Volumn 22, Issue 2, 2014, Pages 148-154

  Singh, Sarvesh Pal ^a   Chauhan, Sandeep ^a   Choudhury, Minati ^a   Malik, Vishwas ^a   Choudhary, Shiv Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Blood loss; Cardiac surgical procedures; Factor VIIa; Postoperative hemorrhage; Recombinant proteins; surgical

Indexed keywords

BLOOD CLOTTING FACTOR 7; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD; CARDIOVASCULAR SURGERY; CONTROLLED STUDY; CRYOPRECIPITATE; FEMALE; HEART SURGERY; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPERATING ROOM; POSTOPERATIVE HEMORRHAGE; THROMBOSIS;

BLOOD LOSS; CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; SURGICAL;

ADOLESCENT; ADULT; AGE FACTORS; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FACTOR VIIA; FEMALE; HEMOSTATICS; HUMANS; INDIA; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; OPERATING ROOMS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; REOPERATION; RETROSPECTIVE STUDIES; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892918379     PISSN: 02184923     EISSN: 18165370     Source Type: Journal    
DOI: 10.1177/0218492312471672     Document Type: Article

References (20)

1. Highlights of Prescribing Information. Available at: http://www.fda.gov/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/ucm089232.htm. Accessed November 28, 2012.
2. Kim WJ, Oh JY, Son HJ, et al. The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection. A case report. Korean J Anesthesiol. 2011 ; 61: 431-434
3. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007 ; 83: 707-714
4. Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Eur J Cardiothorac Surg 2011; 40: 1320-1327.
5. McQuilten ZK, Barnes C, Zatta A, Phillips LE, Haemostasis Registry Steering Committee. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics. 2012 ; 129: e1533-1540
6. Winch PD, Naguib AN, Bradshaw JR, Galantowicz M, Tobias JD. Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa. Pediatr Cardiol. Epub ahead of print 4 July 2012.
7. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005 ; 95: 596-602
8. Chuansumrit A, Teeraratkul S, Wanichkul S, et al. Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients. Blood Coagul Fibrinolysis. 2010 ; 21: 354-362
9. Kylasam S, Mos K, Fijtin S, Webster B, Chard R, Egan J. Recombinant activated factor VII following pediatric cardiac surgery. J Intensive Care Med. 2009 ; 24: 116-121
10. Dinardo JA Pediatric Cardiac Anesthesia. 4 th ed. Philadelphia: Lippincott Williams and Wilkins, 2005, pp. 240-240. Lake CL Booker PD editors, ed. Philadelphia: Lippincott Williams and Wilkins ; 2005: 240-240.
11. Karkouti K, Levy JH. Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg. 2011 ; 113: 711-712
12. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006 ; 124: 747-757
13. Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG Wintrobe's Clinical Hematology. 12 th ed. Philadelphia: Lippincott Williams and Wilkins, 2009, pp. 543-543. Greer JP Forester J Rodgers GM Paraskevas F Glader B, ed. Philadelphia: Lippincott Williams and Wilkins ; 2009: 543-543.
14. Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience. Ann Thorac Surg. 2010 ; 89: 570-576
15. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg. 2007 ; 84: 161-169
16. Singh SP, Chauhan S, Choudhary M, Vasdev S, Talwar S. Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery. Asian Cardiovasc Thorac Ann. 2012 ; 20: 19-23
17. Warren OJ, Rogers PL, Watret AL, et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here [Review]? Pediatr Crit Care Med 2009; 10: 572-82.
18. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004 ; 44: 1325-1331
19. Novo Nordisk Inc. Novoseven@RT (package insert). Denmark: Novo Nordisk, Inc., 2012.
20. Oliver WC Pediatric Cardiac Anesthesia. 4 th ed. Philadelphia: Lippincott Williams and Wilkins, 2005, pp. 314-314. Lake CL Booker PD editors, ed. Philadelphia: Lippincott Williams and Wilkins ; 2005: 314-314.